TR201908660T4 - TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE. - Google Patents

TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE. Download PDF

Info

Publication number
TR201908660T4
TR201908660T4 TR2019/08660T TR201908660T TR201908660T4 TR 201908660 T4 TR201908660 T4 TR 201908660T4 TR 2019/08660 T TR2019/08660 T TR 2019/08660T TR 201908660 T TR201908660 T TR 201908660T TR 201908660 T4 TR201908660 T4 TR 201908660T4
Authority
TR
Turkey
Prior art keywords
naltrexone
subject
phase
rna
administered
Prior art date
Application number
TR2019/08660T
Other languages
English (en)
Turkish (tr)
Inventor
Dalgleish Angus
Liu Wai
Original Assignee
Cancer Vaccine Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Vaccine Inst filed Critical Cancer Vaccine Inst
Publication of TR201908660T4 publication Critical patent/TR201908660T4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TR2019/08660T 2014-06-09 2015-06-09 TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE. TR201908660T4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1410216.4A GB201410216D0 (en) 2014-06-09 2014-06-09 Therapeutic

Publications (1)

Publication Number Publication Date
TR201908660T4 true TR201908660T4 (en) 2019-07-22

Family

ID=51266919

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08660T TR201908660T4 (en) 2014-06-09 2015-06-09 TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE.

Country Status (10)

Country Link
US (3) US11065245B2 (enExample)
EP (1) EP3151831B1 (enExample)
JP (1) JP6620338B2 (enExample)
DK (1) DK3151831T3 (enExample)
ES (1) ES2730348T3 (enExample)
GB (1) GB201410216D0 (enExample)
PL (1) PL3151831T3 (enExample)
PT (1) PT3151831T (enExample)
TR (1) TR201908660T4 (enExample)
WO (1) WO2015189597A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
GB201704913D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Method
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
JP7584431B2 (ja) * 2019-03-06 2024-11-15 エルディーエヌ ファーマ リミテッド 治療のモニタリング方法
JP7502320B2 (ja) * 2019-03-06 2024-06-18 エルディーエヌ ファーマ リミテッド 効力を判定するための方法
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
CN114364402A (zh) 2019-07-15 2022-04-15 罗瓦萨公司 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂，特别是纳洛酮和/或纳曲酮

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
JP2015107918A (ja) * 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic

Also Published As

Publication number Publication date
US20250032481A1 (en) 2025-01-30
US11065245B2 (en) 2021-07-20
DK3151831T3 (da) 2019-06-24
JP2017519006A (ja) 2017-07-13
ES2730348T3 (es) 2019-11-11
US20210308125A1 (en) 2021-10-07
US20170119755A1 (en) 2017-05-04
GB201410216D0 (en) 2014-07-23
US12144807B2 (en) 2024-11-19
EP3151831A1 (en) 2017-04-12
PT3151831T (pt) 2019-06-18
PL3151831T3 (pl) 2021-05-31
EP3151831B1 (en) 2019-03-13
WO2015189597A1 (en) 2015-12-17
JP6620338B2 (ja) 2019-12-18

Similar Documents

Publication Publication Date Title
Di Caprio et al. Anti‐inflammatory properties of low and high doxycycline doses: an in vitro study
Schmulson et al. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review
NZ712823A (en) Molecular diagnostic test for cancer
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
EP4140487A8 (en) Combination therapy for treating cancer
Stefanaki et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study
Harada et al. Dose-and time-dependent effects of triamcinolone acetonide on human rotator cuff-derived cells
MX2020009999A (es) Composiciones farmacéuticas para inhibir citocinas inflamatorias.
JP2017519006A5 (enExample)
Aguilar et al. Interaction between Campylobacter and intestinal epithelial cells leads to a different proinflammatory response in human and porcine host
WO2019118793A3 (en) Subject-specific tumor inhibiting cells and the use thereof
WO2017087947A3 (en) Method of treatment of follicular lymphoma with a btk inhibitor
Breccia et al. How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages
MX2022004571A (es) Alquilésteres de alfa-metil-dl-tirosina para uso en el tratamiento de cáncer.
Polytarchou et al. X-rays affect the expression of genes involved in angiogenesis
Young et al. JAK1/2 regulates synergy between interferon gamma and lipopolysaccharides in microglia
MX2023002416A (es) Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina.
MX2022005900A (es) Agentes antisentido de il-34 y metodos de uso de los mismos.
EA202192330A1 (ru) Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения
JP2009529037A5 (enExample)
Yu et al. Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression
HRP20250112T1 (hr) Osiromašenje b-stanica kao dijagnostički marker
Terai et al. Clinical features of partial atrophic tongue associated with Candida